AVTE 外汇新闻
Aerovate Says Phase 2b Portion Of Trial Of AV-101 Fails To Meet Primary And Secondary Endpoints
Biopharmaceutical company Aerovate Therapeutics, Inc. (AVTE) announced Monday topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial of AV-101.
RTTNews
|
142天前
